Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CACarisma Therapeutics, Inc. logo

Carisma Therapeutics, Inc. (CARM)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.03
52 Week Range
$0.00 – $0.10
Volume
10,296
Avg. Volume
24,241
Market Cap
$8.37K
Beta (5Y Monthly)
-9.60
PE Ratio (TTM)
0.00
EPS (TTM)
$0.84
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Mar 8, 2023
1y Target Est
$6.00

Profile: Carisma Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
46
CEO
Craig R. Jalbert

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.12 · Revenue est. $4.66M
DateEst.Actual
Nov 12, 2025–$1.07
Aug 7, 2025-$0.12-$0.12Beat
May 13, 2025-$0.12-$0.22Miss
Mar 31, 2025-$0.16-$0.42Miss
Nov 7, 2024-$0.31-$0.31Beat
Aug 8, 2024-$0.36-$0.27Beat

Analyst view

Consensus price target
$6.00 ▲ +2,999,900.0%
Range $6.00 – $6.00
Rating: Hold
Buy 33% · Hold 67% · Sell 0%

Get free alerts on CARM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.